GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (NYSE:RMD) » Definitions » Cyclically Adjusted PS Ratio

ResMed (ResMed) Cyclically Adjusted PS Ratio : 9.52 (As of May. 21, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ResMed Cyclically Adjusted PS Ratio?

As of today (2024-05-21), ResMed's current share price is $217.48. ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $22.84. ResMed's Cyclically Adjusted PS Ratio for today is 9.52.

The historical rank and industry rank for ResMed's Cyclically Adjusted PS Ratio or its related term are showing as below:

RMD' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.12   Med: 8.65   Max: 18.37
Current: 9.58

During the past years, ResMed's highest Cyclically Adjusted PS Ratio was 18.37. The lowest was 6.12. And the median was 8.65.

RMD's Cyclically Adjusted PS Ratio is ranked worse than
84.99% of 473 companies
in the Medical Devices & Instruments industry
Industry Median: 2.19 vs RMD: 9.58

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ResMed's adjusted revenue per share data for the three months ended in Mar. 2024 was $8.118. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $22.84 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ResMed Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ResMed's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Cyclically Adjusted PS Ratio Chart

ResMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.54 13.65 15.31 11.09 10.40

ResMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.73 10.40 6.84 7.82 8.67

Competitive Comparison of ResMed's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted PS Ratio falls into.



ResMed Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ResMed's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=217.48/22.84
=9.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ResMed's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=8.118/131.7762*131.7762
=8.118

Current CPI (Mar. 2024) = 131.7762.

ResMed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.900 100.560 3.800
201409 2.666 100.428 3.498
201412 2.974 99.070 3.956
201503 2.958 99.621 3.913
201506 3.170 100.684 4.149
201509 2.893 100.392 3.797
201512 3.214 99.792 4.244
201603 3.214 100.470 4.215
201606 3.661 101.688 4.744
201609 3.276 101.861 4.238
201612 3.733 101.863 4.829
201703 3.603 102.862 4.616
201706 3.900 103.349 4.973
201709 3.650 104.136 4.619
201712 4.180 104.011 5.296
201803 4.109 105.290 5.143
201806 4.323 106.317 5.358
201809 4.084 106.507 5.053
201812 4.511 105.998 5.608
201903 4.588 107.251 5.637
201906 4.865 108.070 5.932
201909 4.694 108.329 5.710
201912 5.057 108.420 6.146
202003 5.282 108.902 6.391
202006 5.271 108.767 6.386
202009 5.147 109.815 6.176
202012 5.464 109.897 6.552
202103 5.283 111.754 6.229
202106 5.975 114.631 6.869
202109 6.156 115.734 7.009
202112 6.086 117.630 6.818
202203 5.882 121.301 6.390
202206 6.220 125.017 6.556
202209 6.459 125.227 6.797
202212 7.013 125.222 7.380
202303 7.578 127.348 7.842
202306 7.601 128.729 7.781
202309 7.474 129.860 7.584
202312 7.881 129.419 8.025
202403 8.118 131.776 8.118

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ResMed  (NYSE:RMD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ResMed Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ResMed's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed (ResMed) Business Description

Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Executives
Brett Sandercock officer: Chief Financial Officer 17 GUINEVIERE COURT, CASTLE HILL, NEW SOUTH WALES C3 2154
Michael J. Farrell officer: Chief Executive Officer C/O REMED INC, 9001 SPECTRUM CTR. BLVD., SAN DIEGO, CA 92123
Michael J Rider officer: Global General Counsel 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Robert Andrew Douglas officer: President and COO 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Kaushik Ghoshal officer: President, SaaS Business 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
David Pendarvis officer: Chief Administration Officer REDMED INC, 14040 DANLELSON ST, POWAY CA 92064
Karen Drexler director C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Justin Leong officer: President, Asia and LATAM C/O RESMED INC, 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Desney Tan director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
John Hernandez director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Lucile Blaise officer: President, Sleep & RC Business RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
James Hollingshead officer: President, Sleep Business C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Carol Burt director C/O WELLCARE HEALTH PLANS, INC., 8725 HENDERSON ROAD, TAMPA FL 33634
Resmed Inc director 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123